ATE553114T1 - Verbindungen zur verminderung der aggregation von amyloid-beta-peptid - Google Patents

Verbindungen zur verminderung der aggregation von amyloid-beta-peptid

Info

Publication number
ATE553114T1
ATE553114T1 AT06727564T AT06727564T ATE553114T1 AT E553114 T1 ATE553114 T1 AT E553114T1 AT 06727564 T AT06727564 T AT 06727564T AT 06727564 T AT06727564 T AT 06727564T AT E553114 T1 ATE553114 T1 AT E553114T1
Authority
AT
Austria
Prior art keywords
compounds
amyloid beta
beta peptide
reducing aggregation
peptide
Prior art date
Application number
AT06727564T
Other languages
English (en)
Inventor
Jan Johansson
Roger Stromberg
Charlotte Nerelius
Hans Leijonmark
Hasmik Sargsyan
Original Assignee
Alphabeta Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alphabeta Ab filed Critical Alphabeta Ab
Application granted granted Critical
Publication of ATE553114T1 publication Critical patent/ATE553114T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/35—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/36—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/47—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT06727564T 2005-02-28 2006-02-28 Verbindungen zur verminderung der aggregation von amyloid-beta-peptid ATE553114T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65733905P 2005-02-28 2005-02-28
PCT/IB2006/001112 WO2006090289A2 (en) 2005-02-28 2006-02-28 Compounds for reducing aggregation of amyloid beta-peptide

Publications (1)

Publication Number Publication Date
ATE553114T1 true ATE553114T1 (de) 2012-04-15

Family

ID=36600156

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06727564T ATE553114T1 (de) 2005-02-28 2006-02-28 Verbindungen zur verminderung der aggregation von amyloid-beta-peptid

Country Status (6)

Country Link
EP (1) EP1858912B1 (de)
JP (1) JP5179198B2 (de)
AT (1) ATE553114T1 (de)
AU (1) AU2006217544B8 (de)
CA (1) CA2599291C (de)
WO (1) WO2006090289A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6716589B2 (en) * 2000-11-20 2004-04-06 Alphabeta Ab Discordant helix stabilization for prevention of amyloid formation
CN102648416A (zh) * 2009-12-07 2012-08-22 宝洁公司 用于评估角蛋白纤维损伤的方法
US10023610B2 (en) 2014-01-17 2018-07-17 Alphabeta Ab Ligands for prevention of neurotoxicity of the alzheimer's disease related amyloid-beta peptide
WO2021090910A1 (ja) * 2019-11-08 2021-05-14 セントラル硝子株式会社 タンパク質凝集塊を検出する分子構造変質剤、その検出方法、医療器具用洗浄剤、土壌洗浄剤及び土壌の洗浄方法
BR112022023734A2 (pt) * 2020-05-24 2023-02-07 Galimedix Therapeutics Inc Formas cristalinas de solvatos de derivados de triptofano, composições que as compreendeem e usos das mesmas
WO2024209060A1 (en) * 2023-04-07 2024-10-10 Université D'aix-Marseille Polyaminated fatty acids for use as potentiators of antibacterial activity

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2463779A (en) * 1947-08-26 1949-03-08 Ernest B Kester N-acylated derivatives of glutamic acid and process for preparing them
US2925639A (en) * 1953-11-30 1960-02-23 Deering Milliken Res Corp Method of fulling and scouring wool
FR1381790A (fr) * 1963-02-22 1964-12-14 Ciba Geigy Procédé servant à la modification des polyamides
DE2136673A1 (de) * 1971-07-22 1973-02-01 Henkel & Cie Gmbh Weichmachendes waschmittel
AU474211B2 (en) * 1972-12-22 1974-06-27 Dunlop Australia Limited Application for polyrethane emulsions to wool
DE2509743A1 (de) * 1975-03-06 1976-09-23 Basf Ag Geschirrspuelmittel
AU3203489A (en) * 1988-02-19 1989-09-22 Upjohn Company, The Lipophilic polyamines useful for treating hypercholesterolemia
CA2277519A1 (en) * 1997-01-10 1998-07-16 Massachusetts Institute Of Technology Treatments for neurotoxicity in alzheimer's disease by .beta.-amyloid peptides
AU781044B2 (en) * 1999-11-05 2005-05-05 Axonyx, Inc. Peptide analogs and mimetics suitable for in vivo use in the treatment of diseases associated with abnormal protein folding into amyloid, amyloid-like deposits or beta-sheet rich pathological precursor thereof
US6716589B2 (en) * 2000-11-20 2004-04-06 Alphabeta Ab Discordant helix stabilization for prevention of amyloid formation
JP5026655B2 (ja) * 2001-04-18 2012-09-12 プロメティック、バイオサイエンシーズ、インコーポレーテッド 好中球の生存及び活性化因子としての中鎖脂肪酸、グリセリド及び類似体
WO2006003877A1 (ja) * 2004-06-30 2006-01-12 Dainippon Sumitomo Pharma Co., Ltd. 受容体リガンド

Also Published As

Publication number Publication date
WO2006090289A8 (en) 2007-03-08
AU2006217544B2 (en) 2012-03-22
CA2599291C (en) 2013-12-31
WO2006090289A2 (en) 2006-08-31
AU2006217544B8 (en) 2012-04-05
AU2006217544A1 (en) 2006-08-31
JP2008535786A (ja) 2008-09-04
WO2006090289A3 (en) 2006-12-07
EP1858912B1 (de) 2012-04-11
CA2599291A1 (en) 2006-08-31
JP5179198B2 (ja) 2013-04-10
EP1858912A2 (de) 2007-11-28

Similar Documents

Publication Publication Date Title
CY1109985T1 (el) Αναστολεις πρωτεασωματος και μεθοδοι χρησης αυτων
EA200901166A1 (ru) Соединения и композиции в качестве модуляторов активности gpr 119
MX2009000285A (es) Piperidinas sustituidas que incrementan la actividad de p53 y usos de las mismas.
ATE506951T1 (de) Als inhibitoren von beta-secretase aktive tertiäre carbinamine mit substituierten heterocyclen zur behandlung der alzheimer- krankheit
CY1116754T1 (el) Παραγωγα νιτροκατεχολης ως αναστολεις της comt
ATE361067T1 (de) Naphtoquinone derivate als inhibitoren von tau aggregation zur behandlung von alzheimer's und verbundenen neurodegenerativen erkrankungen
EA201171439A1 (ru) Соединение альфа-(n-сульфонамидо)ацетамида в качестве ингибитора продуцирования бета-амилоидного пептида
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
MX2023009652A (es) Inhibidores peptidicos de la acumulacion de alfa-sinucleina basados en estructuras.
DE602004014117D1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
MX2022005782A (es) Anticuerpos monoclonales contra la proteina amiloide beta y usos de los mismos.
IS3013B (is) Meltikornatálmar og aðferðir til að nota þá
EA201071245A1 (ru) Новые терапевтические подходы для лечения болезни альцгеймера и связанных нарушений посредством модулирования реакции клеток на стресс
ATE415397T1 (de) Substituierte aryl- und heteroarylderivate als modulatoren des stoffwechsels und für die prophylaxe und behandlung von damit in zusammenhang stehenden erkrankungen
NO20064726L (no) Imidazolforbindelser for behandling av neurodegenerative forstyrrelser
DE602004009295D1 (de) 1,2,3-trisubstituierte aryl- und heteroarylderivate als modulatoren des metabolismus zur vorbeugung und behandlung von metabolismus-bedingten krankheiten wie diabetes oder hyperglykämie
ATE538651T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
CL2011001098A1 (es) Compuestos derivados de 4-fluoro-1h-isoindol-3-amina; inhibidores de b-secretasa (bace); composicion farmaceutica; y su uso para el tratamiento o prevencion de una patologia relacionada con la proteina beta amiloide tal como sindrome de down, alzheimer, demencia senil y demencia asociada con parkinson, entre otras.
DE602005019078D1 (de) Piperidine und verwandte verbindungen zur behandlung von alzheimer-krankheit
MX2020001855A (es) Composiciones farmacéuticas que contienen anticuerpos anti-beta-amiloides.
MX2019003805A (es) Activadores de flujo autofágico y fosfolipasa d y depuración de acumulaciones de proteína que incluyen tau y tratamiento de proteinopatías.
ATE472998T1 (de) Kationische liposomale zubereitungen zur behandlung von rheumatoider arthritis
PH12021552358A1 (en) Compounds and compositions as modulators of tlr signaling
ATE512147T1 (de) Makrozyklische aminiopyridyl-beta-sekretase- hemmer zur behandlung von morbus alzheimer
ATE530525T1 (de) Piperidine und verwandte verbindungen zur behandlung von demenz